These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33001014)

  • 1. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
    Lingasamy P; Laarmann AH; Teesalu T
    Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-penetrating peptide for systemic targeting of Tenascin-C.
    Lingasamy P; Tobi A; Kurm K; Kopanchuk S; Sudakov A; Salumäe M; Rätsep T; Asser T; Bjerkvig R; Teesalu T
    Sci Rep; 2020 Apr; 10(1):5809. PubMed ID: 32242067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
    Yagolovich AV; Isakova AA; Artykov AA; Vorontsova YV; Mazur DV; Antipova NV; Pavlyukov MS; Shakhparonov MI; Gileva AM; Markvicheva EA; Plotnikova EA; Pankratov AA; Kirpichnikov MP; Gasparian ME; Dolgikh DA
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
    Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
    J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
    Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
    Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
    Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
    Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.
    Silacci M; Brack SS; Späth N; Buck A; Hillinger S; Arni S; Weder W; Zardi L; Neri D
    Protein Eng Des Sel; 2006 Oct; 19(10):471-8. PubMed ID: 16928692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical advances in TNC delivery vectors and their conjugate agents.
    Chen W; Wu Y; Wang J; Yu W; Shen X; Zhao K; Liang B; Hu X; Wang S; Jiang H; Liu X; Zhang M; Xing X; Wang C; Xing D
    Pharmacol Ther; 2024 Jan; 253():108577. PubMed ID: 38081519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased antitumor activity of tumor-specific peptide modified thymopentin.
    Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
    Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
    Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
    Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery.
    Lingasamy P; Tobi A; Haugas M; Hunt H; Paiste P; Asser T; Rätsep T; Kotamraju VR; Bjerkvig R; Teesalu T
    Biomaterials; 2019 Oct; 219():119373. PubMed ID: 31374479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
    Lao X; Liu M; Chen J; Zheng H
    PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
    Hu C; Chen X; Huang Y; Chen Y
    Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
    E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C.
    Kobayashi N; Odaka K; Uehara T; Imanaka-Yoshida K; Kato Y; Oyama H; Tadokoro H; Akizawa H; Tanada S; Hiroe M; Fukumura T; Komuro I; Arano Y; Yoshida T; Irie T
    Anal Chem; 2011 Dec; 83(23):9123-30. PubMed ID: 22074352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.